An in-depth analysis of KRAS-targeted drugs: Is the Chinese name of AMG510 sotoraxib?

AMG510, the drug behind this code name, actually has a more familiar name in the Chinese environment - sotoracib. This is a targeted drug targeting the KRASG12C mutation developed by the biotechnology company Amgen and is currently in the critical stage of clinical trials. As an oral small molecule inhibitor, sotoraxib is unique in that it can accurately recognize and bind to the KRAS G12C mutant protein, thereby blocking the abnormal cell signaling caused by it. This mutation is widely present in various tumors such as non-small cell lung cancer and is considered to be one of the key drivers of tumor occurrence and development.

The KRAS protein plays an important role in the cell signaling network. When it undergoes G12C mutation, it will lead to uncontrolled cell proliferation and proliferation, thereby promoting the formation and progression of tumors. The development of sotoracib is precisely to provide new treatment strategies for this fatal mutation. By inhibiting the activity of the KRAS G12C mutant protein, sotoraxib is expected to bring new treatment options and hope to those with KRAS G12C-positive cancer patients.

The development of sotorasiib represents a major breakthrough in the field of targeted therapy for KRAS mutations. For a long time, due to the structural complexity and diversity of regulatory mechanisms of KRAS proteins, targeted therapy has been regarded as an insurmountable challenge. However, the emergence of sotoracib has changed this situation and opened up a new path for precision treatment of KRAS mutations. At present, sotoracib has been approved for marketing in many regions around the world, including the United States, the European Union and Canada, and its trade names include Lumakras, Lumykras, etc. This means that for those patients with KRAS G12C-positive cancer, sotoraxib has become a new and effective treatment option.